BiotechTube
Idience

Idience

San Diego, United States· Est.
idience.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $5M

Overview

Idience is a private, clinical-stage biotech headquartered in San Diego, USA, but founded and wholly owned by Korea's Ildong Holdings. Its lead asset is venadaparib (IDX-1197), a potent PARP inhibitor with FDA Fast Track designation, currently in Phase 1b/2a trials for gastric cancer and other solid tumors. The company operates with a lean, experienced leadership team and a pipeline centered on targeted small molecule therapies, positioning it in the competitive but high-value oncology precision medicine space.

Oncology

Technology Platform

Focused on discovery and development of targeted small molecule inhibitors, with core expertise in DNA Damage Response (DDR) pathways, specifically PARP inhibition.

Funding History

1
Total raised:$5M
Seed$5M

Opportunities

The FDA Fast Track designation for venadaparib in gastric cancer provides an expedited development path in a high-unmet-need oncology niche.
Success in clinical trials could lead to lucrative partnership deals for global development and commercialization, particularly outside of Asia.

Risk Factors

High dependency on a single clinical asset (venadaparib) and on continued funding from its parent company, Ildong Holdings.
Faces intense competition from established, commercially successful PARP inhibitors in a crowded market, making differentiation critical.

Competitive Landscape

Idience competes in the mature and competitive PARP inhibitor market against giants like AstraZeneca/Merck (olaparib), GSK (niraparib), and Clovis Oncology (rucaparib). Its strategy relies on demonstrating best-in-class properties for venadaparib and targeting specific indications like gastric cancer where competitors are less entrenched.

More companies in Diagnostics & Precision Medicine →More companies in United States →